Oruka Therapeutics announced on Monday that its long-acting injectable therapy, ORKA-001, achieved complete skin clearance in 63% of patients with plaque psoriasis during a mid-stage clinical trial.
The company also revealed an updated analysis of blood exposure levels, reinforcing the drug’s potential to be administered just once per year.
While Oruka must still conduct late-stage clinical trials, the Monday results highlight ORKA-001’s promise as a new treatment for the autoimmune skin condition. Its remission rates may match or exceed current leading therapies, Skyrizi and Bimzelx, while requiring fewer injections.
Related articles
FDA Drug Center Acting Director Tracy Beth Høeg Departs Amid Leadership Changes
WASHINGTON — The acting director of the Food and Drug Administration’s drug center, Tracy Beth Høeg, is leaving the agency, according to three sources...
STAT+ Roundup: New Hires and Promotions in Biotech and Pharma
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others....
U.S. Pressures Germany to Increase Payments for Prescription Drugs Amid Trade Tensions
WASHINGTON — Over a recent breakfast, U.S. officials had a message for the German ambassador: pay more for pharmaceuticals. The meeting, between U.S....
PSA Screening Significantly Lowers Prostate Cancer Death Risk, Cochrane Review Confirms
Prostate-specific antigen (PSA) blood testing is likely to reduce the risk of death from prostate cancer, found a new review published on Thursday by...
Dr. Makary's Exit and the Future of Cassidy's Senate Seat: Key Health Policy Shifts
This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he...
BeOne Secures FDA Approval for Novel Lymphoma Cell Therapy, Advancing Autoimmune Treatment Pipeline
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Biotech’s cell therapy boo...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Phase 2 Trial; Takeda to Cut 4,500 Jobs by 2026
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue ski...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Mid-Stage Trial
Biogen reported mixed results Thursday from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tau...